Information de reference pour ce titreAccession Number: | 00000381-201805000-00014.
|
Author: | Kortekaas Krohn, I. 1; Callebaut, I. 2; Alpizar, Y. A. 3; Steelant, B. 1; Van Gerven, L. 2; Skov, P. S. 4; Kasran, A. 1; Talavera, K. 3; Wouters, M. M. 5; Ceuppens, J. L. 1; Seys, S. F. 1; Hellings, P. W. *,1,2,6,7
|
Institution: | (1)Laboratory of Clinical Immunology Department Microbiology & Immunology KU Leuven Leuven Belgium (2)Clinical Division of Otorhinolaryngology, Head and Neck Surgery University Hospitals Leuven Leuven Belgium (3)Department of Cellular and Molecular Medicine Laboratory of Ion Channel Research VIB Center for Brain & Disease Research KU Leuven Leuven Belgium (4)RefLab Copenhagen Denmark (5)Translational Research Center for Gastro Intestinal Disorders (TARGID) KU Leuven Leuven Belgium (6)Clinical Division of Otorhinolaryngology, Head and Neck Surgery Academic Medical Center Amsterdam the Netherlands (7)Upper Airways Research Laboratory University of Ghent Ghent Belgium
|
Title: | |
Source: | Allergy. 73(5):1084-1093, May 2018.
|
Author Keywords: | allergic rhinitis; azelastine hydrochloride; fluticasone propionate; nasal hyperreactivity; substance P.
|
References: | 1. Van Gerven L, Boeckxstaens G, Hellings P. Up-date on neuro-immune mechanisms involved in allergic and non-allergic rhinitis. Rhinology. 2012;50:227-235.
2. Salib RJ, Harries PG, Nair SB, Howarth PH. Mechanisms and mediators of nasal symptoms in non-allergic rhinitis. Clin Exp Allergy. 2008;38:393-404.
3. Segboer CL, Holland CT, Reinartz SM, et al. Nasal hyper-reactivity is a common feature in both allergic and nonallergic rhinitis. Allergy. 2013;68:1427-1434.
4. van der Kleij HPM, Ma D, Redegeld FAM, Kraneveld AD, Nijkamp FP, Bienenstock J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol. 2003;171:2074-2079.
5. Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65:155-168.
6. Hox V, Vanoirbeek JA, Alpizar YA, et al. Crucial role of transient receptor potential ankyrin 1 and mast cells in induction of nonallergic airway hyperreactivity in mice. Am J Respir Crit Care Med. 2013;187:486-493.
7. Van Gerven L, Alpizar YA, Wouters MM, et al. Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis. J Allergy Clin Immunol. 2014;133:1332-1339.
8. Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150:875-887.
9. Trankner D, Hahne N, Sugino K, Hoon MA, Zuker C. Population of sensory neurons essential for asthmatic hyperreactivity of inflamed airways. Proc Natl Acad Sci U S A. 2014;111:11515-11520.
10. Talbot S, Abdulnour R-EE, Burkett PR, et al. Silencing nociceptor neurons reduces allergic airway inflammation. Neuron. 2015;87:341-354.
11. Klimek L, Bousquet J, Price D. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opin Drug Saf. januari 2016;15:117-129.
12. Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2:179-185.
13. Klimek L, Bachert C, Mosges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36:40-47.
14. Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23:495-503.
15. Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015;16:913-928.
16. Derendorf H, Meltzer EO, Hermann R, Canonica GW. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs Today. 2014;50:15-31.
17. Berger W, Bousquet J, Fox AT, et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016;71:1219-1222.
18. Bernstein JA. MP29-02: a breakthrough for the treatment of allergic rhinitis. Expert Opin Pharmacother. 2013;14:2101-2113.
19. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1282-1289.
20. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33:324-332.
21. Steelant B, Farre R, Wawrzyniak P, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 2016;137:1043-1053.
22. Heijink IH, Jonker MR, de Vries M, et al. Budesonide and fluticasone propionate differentially affect the airway epithelial barrier. Respir Res. 2016;17:2.
23. Van Gerven L, Boeckxstaens G, Jorissen M, Fokkens W, Hellings PW. Short-time cold dry air exposure: a useful diagnostic tool for nasal hyperresponsiveness. Laryngoscope. 2012;122:2615-2620.
24. Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy. 2009;64:1516-1523.
25. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43:881-888.
26. Demoly P, Calderon MA, Casale T, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013;3:7.
27. Callebaut I, De Vries A, Steelant B, et al. Nasal allergen deposition leads to conjunctival mast cell degranulation in allergic rhinoconjunctivitis. Am J Rhinol Allergy. 2014;28:290-296.
28. Holm M, Andersen HB, Hetland TE, et al. Seven week culture of functional human mast cells from buffy coat preparations. J Immunol Methods. 2008;336:213-221.
29. Krohn IK, Sverrild A, Lund G, et al. Cultured mast cells from patients with asthma and controls respond with similar sensitivity to recombinant Der p2-induced, IgE-mediated activation. Scand J Immunol. 2013;78:352-356.
30. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003;112:819-829.
31. Meseguer VM, Denlinger BL, Talavera K. Methodological considerations to understand the sensory function of TRP channels. Curr Pharm Biotechnol. 2011;12:3-11.
32. Alpizar YA, Gees M, Sanchez A, et al. Bimodal effects of cinnamaldehyde and camphor on mouse TRPA1. Pflugers Arch. 2013;465:853-864.
33. Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. The effect of azelastine on the early allergic response. Clin Exp Allergy. 1992;22:289-295.
34. Takao A, Shimoda T, Matsuse H, et al. Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma. Ann Allergy Asthma Immunol. 1999;82:390-394.
35. Nieber K, Baumgarten C, Rathsack R, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy. 1993;23:69-71.
36. Jacobi HH, Skov PS, Poulsen LK, Malling HJ, Mygind N. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol. 1999;103:768-772.
37. Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol. 2003;132:231-239.
38. Lytinas M, Kempuraj D, Huang M, et al. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc. 2002;23:45-51.
39. Catalli A, Karpov V, Erdos LE, Tancowny BP, Schleimer RP, Kulka M. Stimulus-selective regulation of human mast cell gene expression, degranulation and leukotriene production by fluticasone and salmeterol. PLoS One. 2014;9:e96891.
40. Akabane H, Murata M, Kubota M, et al. Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells. Allergol Int. 2006;55:387-393.
41. Bernstein JA, Davis BP, Picard JK, Cooper JP, Zheng S, Levin LS. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol. 2011;107:171-178.
42. Singh U, Bernstein JA, Haar L, Luther K, Jones WK. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy. 2014;28:215-224.
43. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490-502.
|
Language: | English.
|
Document Type: | ORIGINAL ARTICLES.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0105-4538
|
NLM Journal Code: | 39c, 7804028
|
DOI Number: | https://dx.doi.org/10.1111/all.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|